FDA Rationale for Recognition Decision: Isavuconazonium sulfate
FDA Rationale for Recognition Decision: Isavuconazonium sulfate
Rusfertide Gains Breakthrough Therapy Designation for Polycythemia Vera
The action follows phase 3 trial data that demonstrated reduced phlebotomy dependence, improved hematocrit control, and eased symptoms.
FDA Expands Evolocumab to Treat Adults at Increased Risk for Major Adverse Cardiovascular Events
Evolocumab is now indicated for adults at increased risk for major adverse cardiovascular events (MACE).
Patients With Systemic Sclerosis Face Decreased HDL-C, Increased Lipoprotein(a)
A systematic review and meta-analysis revealed key insights into lipid parameters in patient with systemic sclerosis.
Op-Ed: Why Banning PBM-Owned Pharmacies Risks Patient Care
State policymakers should target bad actors while protecting access.
US-bound shipments restricted by postal carriers in Europe, Asia
Operators said uncertain guidelines and a short window before the de minimis exemption ends Aug. 29 prompted the suspension of…
Supreme Court allows NIH to axe millions of research funds related to DEI
The Thursday ruling allows the National Institutes of Health to cut nearly $800 million of research funds for studies like HIV…
CIO Podcast – Episode 101: Digital Messaging with Tom Gillette
For the 101st episode of the CIO podcast hosted by Healthcare IT Today, we are joined by Tom Gillette, CIO…
Oracle Health’s market share declined ‘substantially’ after Cerner buy: report
The company has lost 57 unique acute care customers in the past three years, 12 of which are larger health…
Bridging the Gap Between Hospital Data and Medical AI
The following is a guest article by Benji Meltzer, Chief Data Officer at Gradient Health Reliable data is the foundation…